Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African developing country setting.
- To evaluate the cost-effectiveness of a short-course zidovudine program to prevent perinatal transmission of human immunodeficiency virus (HIV) type 1 in sub-Saharan African country settings.
Design and Setting
- Several clinical trials of short-course zidovudine during pregnancy for prevention of perinatal transmission of HIV are under way in developing countries in sub-Saharan Africa.
A decision model was used to examine the cost-effectiveness of zidovudine programs in a hypothetical 1-year birth cohort in a sub-Saharan African setting from the perspective of the health care system and of society.
A completed short course of zidovudine was assumed to reduce perinatal HIV transmission from 25% to 16.5%, approximately one half of the effect of the longer-course zidovudine.
Estimates of program costs, lifetime HIV-related health care costs, and lost productivity costs were derived from the published literature and from preliminary data available from sites of planned clinical trials.
Sensitivity analyses were conducted on all relevant parameters.
Main Outcome Measures
- Medical costs, lost productivity costs, program costs, cost savings, and incremental cost-effectiveness, expressed as cost per infant HIV infection prevented.
- The model estimated that a national zidovudine program in a setting with 12.5% HIV seroprevalence would reduce perinatal HIV incidence by 12% (4.9 infections per 1000 births). (...)
Mots-clés Pascal : Coût, Traitement, Prévention, Zidovudine, Infection, Virus HIV1, Virus immunodéficience humaine, Lentivirinae, Retroviridae, Virus, Périnatal, Afrique, Etude cohorte, Economie, Nouveau né, Homme, Adulte, Essai clinique, Pyrimidine nucléoside, Antiviral
Mots-clés Pascal anglais : Costs, Treatment, Prevention, Infection, HIV-1 virus, Human immunodeficiency virus, Lentivirinae, Retroviridae, Virus, Perinatal, Africa, Cohort study, Economy, Newborn, Human, Adult, Clinical trial, Pyrimidine nucleoside, Antiviral
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0352357
Code Inist : 002B30A04B. Création : 10/04/1997.